McBride KE, Steffens D, Solomon MJ, et al. - Via this study, researchers sought to inscribe the detailed in-hospital costs of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of patients with peritoneal malignancy compared with an Australian Activity Based Funding (ABF) system. Further, they evaluated how the learning curve, disease entities and surgical outcomes affect in-hospital costs. They analyzed 118 CRS and HIPEC procedures undertaken at a large public tertiary referral hospital in Sydney, Australia from April 2017 to June 2019 and identified these to be associated with the median total cost of AU$130,804 (IQR: 105,744 to 153,972). Provision of funding via the ABF system was nearly one-third of the total CRS and HIPEC costs. Findings here suggest expensiveness of delivering CRS and HIPEC with high variability. They observed gross underestimation of the specific CRS and HIPEC funding needed with supplementation essential to sustaining this complex highly specialised service by a standard ABF system.